戻る Agenda
Poster Session and Networking Reception
Speaker(s)
The Effects of Chiral Control on the Pharmacologic Properties of Antisense Oligonucleotides
Nancy Griffith, PhD
Wave Life Sciences, United States
A Targeted Nanocomplex that Actively Ferries Therapeutic Nucleic Acids Across the Blood-Brain Barrier
Joe Harford, PhD
SynerGene Therapeutics, Inc., United States
President & CEO
DMD Exon 51 Skipping Efficiency and Dystrophin Protein Restoration Induced by WVE-210201: An Investigational Stereopure ASO
Zhong Zhong
Wave Life Sciences, United States
Vice President, Biology
miRNA-Loaded Lipid Nanoparticles for Ovarian Cancer Treatment
Petra Kos, PhD, MPharm
UT Southwestern Medical Center, United States
Postdoctoral Fellow
Preclinical Studies of WVE-120101 and WVE-12010: Investigational Stereopure ASOs for Huntington’s Disease (HD)
Meena Meena, PhD
Wave Life Sciences, United States
Senior Director
Impurity and Failure sequence Profile Change Due to Omission of the Capping Step in Synthesis of PS/PO Mixed Backbone ASOs
Hong Jiang, MS
Leal Therapeutics, United States
Scientist I
Quality Aspects of mRNA Drug Products: How Do We Control Identity, Purity, and Potency?
Silke Klick, PhD
AstraZeneca, Sweden
Regulatory Director CMC
A Control Strategy for GMP Manufacturing of Antisense Oligonucleotides Based on a Liquid DS Platform
Ruiting Liang, PhD
Alkermes, United States
Senior Scientist
Development of a Novel Therapeutic Splice-Switching Oligonucleotide Targeting Race-Related Aggressive Prostate Cancer
Jennifer Freedman, PhD
Duke Cancer Institute, United States
Assistant Professor
Translatability of miR-29 PD Biomarkers from Preclinical Models to Mechanistic Proof of Concept in an MRG-201 Clinical Trial
Corrie L Gallant-Behm, PhD
Miragen Therapeutics, Inc., United States
Research Scientist III
Dual Function Oligonucleotide CpG-STAT3 Inhibitor for B-Cell Lymphoma Immunotherapy
Marcin Kortylewski, PhD, MS
City Of Hope, Beckman Research Institute, United States
Professor
Ultra-Sensitive Locked Nucleic Acid Hybridization-Ligation ECL ELISA for Quantitative Measurement of siRNA
Mai Bailey Thayer, MS
Amgen Inc., United States
Senior Associate Scientist
Comparison of Subcutaneous and Intravenous Routes of Administration for Liver-Targeted RNAi Agents: Effect of PK-Modulating
Girish R Chopda, PhD
Dicerna Pharmaceuticals, United States
Associate Director, Nonclinical Development
Innate Immune Focused Approaches to Maximize Messenger RNA Therapeutic Activity
Josh Whisenand
TriLink BioTechnologies, United States
Pharmacokinetic and Safety Data in Monkey and Human After IV Bolus Administration of MRG-106: An Inhibitor of miR-155
Brent Allen Dickinson
Miragen Therapeutics, United States
Manager, Pharmacokinetics
Phase 1 Trial Evaluating MRG-106: A Synthetic Inhibitor of microRNA-155 in CTCL Patients
Anita G Seto, PhD
miRagen Therapeutics, United States
Associate Director, Translational Sciences